PubMed Health⌕ Search

Biomedical subjects

V G Popov

Publications and source records attributed to V G Popov.

At least 19 recordsLinked to original sources
PubMed1995

[The use of tactivin for treating patients with IHD].

Immunomodulating drug tactivin was used for treatment of 29 IHD patients with low T-suppressor activity and high cell sensitization to apoprotein B-containing lipoproteins and with lipoprotein-antibody immune complex detected in the blood. Tactivin was injected subcutaneously in the dose 10 micrograms (5 injections for 12 days). Tactivin treatment normalized T-suppressor activity, lowered concentration of plasma lipoprotein-antibody immune complex and improved clinical course of IHD. The beneficial effect of tactivin was observed in 70% of patients during 2 months. 30% of patients needed a second course of treatment of recover normal immunological and clinical indices. The treatment with tactivin of IHD patients must be combined with application of routine antianginal drugs.

Adjuvants, Immunologic↗
PubMed1991

[The role of a spasm of the coronary arteries in the pathogenesis of acute myocardial infarct and in the development of sudden coronary death].

Based on the clinical experience and clinicoanatomic correlations, the authors suggest the role of hemorrhage and rupture of atherosclerotic patches in the pathogenesis of sudden coronary death. Proceeding from long-term follow-up studies of patients suffering from CHD, the necessity is substantiated of the regular use of beta-adrenoblockers which significantly reduce the rate of sudden death both in the acute and chronic phases of CHD, particularly in patients with a history of myocardial infarction. Taking into consideration the multifactorial nature of the pathogenesis of acute occlusion of coronary arteries, it is suggested that in addition to the preventive administration of beta-adrenoblockers, thrombolytic agents in combination with antiaggregation remedies and calcium antagonists should be prescribed, especially in cases of arterial pressure rises.

Aged↗
PubMed1991

[Post-infarction stenocardia (clinical and prognostic significance)].

The impact of postinfarction angina pectoris on the course of myocardial infarction (MI) was studied in the hospital setting in 359 patients who had sustained large MI, 247 of them being followed for a year after their discharge. In the group of patients with postinfarction angina pectoris, the course of the disease was found to be more severe in hospital and during a year-follow-up after MI. They more frequently developed acute and chronic heart failure, rhythm and conduction disturbances, recurrent MI. A statistic relationship was not established between the development of postinfarction angina and late fatality. Postinfarction angina was demonstrated to increase a risk for an unfavorable course of a postinfarction period. No significant difference was found in the prognostic significance of the time angina occurred following MI.

Adult↗
PubMed1990

[Effects of T-activin on the course of ischemic heart disease in cases of the development of sensitization to apoprotein B-containing lipoproteins].

A comprehensive clinicoimmunological examination was made of 105 male patients aged 35-65 years who suffered from coronary heart disease. The authors identified a group of 33 patients whose unstable course of angina pectoris was associated with pronounced apolipoprotein B sensitization, as well as with the presence of the autoimmune lipoprotein-antibody complex and abnormalities in the cellular link of immunity. All 33 patients received antianginal agents. Out of them, 15 patients took additionally a course of T-activin therapy to modulate immunological shifts. The results of the examination demonstrated that the immunomodulator exerted a beneficial effect both on the course of CHD (reduction in the number of anginal episodes, improvement of left ventricular contractility) and the immune system (recovery of T-suppressor function, disappearance of lipoprotein sensitization, decrease in the patient's blood detection rates of the autoimmune lipoprotein-antibody complexes from 83 to 28%). The highest effect was reached by T-activin 1.5-2 months following termination of the course therapy. Immunomodulating therapy is regarded as an additional approach to the treatment of CHD patients with marked lipoprotein sensitization.

Adjuvants, Immunologic↗
PubMed1990

[Clinico-immunologic parallels in evaluating the treatment of multiple sclerosis].

Certain immunological parameters were examined over time in 54 patients afflicted with multiple sclerosis. Nonhormonal multimodality treatment methods including immunomodulatory remedies and corticosteroid hormones were employed. The total counts of T and B lymphocytes as well as their functional activity were found to be related to the disease stage. The pattern of changes in the main factors of immune responsiveness influenced by different types of therapy was established to be inconclusive. Based on an analysis of the clinico-paraclinical parameters it is concluded that conventional multimodality therapy including the use of immunomodulators may be administered both during disease remission and, in some cases, during its exacerbation.

Acute Disease↗
PubMed1989

[Characteristics of the course of ischemic heart disease and diabetes mellitus occurring jointly].

Findings of research into the specific course of ischaemic heart disease (IHD) concurrent with diabetes mellitus are analysed. Diabetic patients were found to have a more severe course of IHD after myocardial infarction, which was more often complicated with arrhythmias, cardiac failure, and unstable angina. The incidence of painless IHD after myocardial infarction was found to be twice higher in diabetics. A consistent relationship between the severity of diabetes and an increase in painless IHD incidence was noted. Diabetes was found to aggravate the IHD course irrespective of the patient's age. A correlation was observed between the severity of IHD and insulinaemia. Certain functional-diagnosis methodologies are shown to be most informative in the differential diagnosis of IHD and diabetic cardiomyopathy. The high efficacy of a complex therapy including beta-blockers and angioprotectors in concurrent IHD and diabetes is demonstrated.

Coronary Disease↗
PubMed1988

[Immunoreactivity in ischemic heart disease of atherosclerotic etiology].

Using a combined immunomorphologic and clinico-immunologic approach to the analysis of section and clinical findings, the authors introduce a specific nosological form of coronary heart disease in which there is a cause-and-effect relation implying the development of sensitization to atherogenic lipoproteins, rapid advance of coronary atherosclerosis and the onset of coronary insufficiency.

Adult↗
PubMed1988

[Characteristics of the course of posterior diaphragmatic myocardial infarction in patients with depression of the ST segment in precordial ECG leads].

The course of acute posterior diaphragmatic myocardial infarction (MI) was evaluated in 82 in-patients, with 47 of those followed up after the discharge. The patients were divided into 2 groups: those without and with ST depression in precordial ECG leads (groups 1 and 2, respectively). MI took a more severe course in the second group. Heart failure and high-grade ventricular extrasystoles were significantly more common both in and after hospital in such patients. Atrioventricular blocks, cardiogenic shock and recurrences during hospital stay prevailed in the second group. After the discharge, they showed a higher mortality rate and significantly more frequent exacerbations of coronary disease, including all cases of repeated macrofocal MI. This suggests that patients with posterior-diaphragmatic MI and ST depression in precordial ECG leads have a poorer immediate and long-term prognosis and can be designated a high-risk group.

Adult↗
PubMed1986

[Streptodecase in myocardial infarction in middle-aged and elderly persons].

A study was made of the effect of a single intravenous injection of streptodecase and heparin in the treatment of elderly and senile patients with myocardial infarction during short-term (under 6 h) and late (over 30 h) periods of development. It was confirmed that streptodecase had a specific selective effect on the fibrinolytic system of the blood, with the risk of the development of hemorrhagic and thromboembolic complications being minimal. Allergic reactions to streptodecase were recorded in 1 out of 12 patients examined. It was marked that streptodecase produced an insignificant prolonged effect while the drug action lasted maximally 48 to 72 h since the moment of administration. The effect of streptodecase depended on the degree of atherosclerotic involvement of the vessels and was more remarkable in elderly and senile persons. No significant differences were found in the efficacy and duration of the action of the drug administered during short-term and late periods of myocardial infarction development. It is not excluded that streptodecase can be used in higher doses or repeatedly in the immediate 36 to 48 h in the treatment of certain patients groups. The combined use of streptodecase and heparin was discovered to be mandatory for restricting the effect of secondary hypercoagulation.

Age Factors↗
PubMed1986

[Inderal in the acute and post-myocardial infarct periods].

The use of propranolol since the first hours of myocardial infarction reduced the perinecrotic zone and restricted the zone of myocardial necrosis, decreased the frequency of arrhythmias and did not produce heart insufficiency. The majority of the patients who had suffered myocardial infarction get rid of angina pectoris under the effect of an individually chosen dose of propranolol. They show a more rapid recovery of the physical activity and work fitness. The authors hold that it is desirable that the patients may receive propranolol continuously throughout many years following myocardial infarction.

Aged↗